A5003013870- Hidradenitis Suppurativa and Treatments
- Colorectal and Anal Carcinomas
- Chemotherapy-related skin toxicity
- Microscopic Colitis
- Anorectal Disease Treatments and Outcomes
- Autoimmune and Inflammatory Disorders
- Streptococcal Infections and Treatments
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Eosinophilic Disorders and Syndromes
- Clinical Reasoning and Diagnostic Skills
- Oral Health Pathology and Treatment
- Antimicrobial Resistance in Staphylococcus
- Cancer Immunotherapy and Biomarkers
- Nail Diseases and Treatments
- Dermatological diseases and infestations
- Innovations in Medical Education
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Psoriasis: Treatment and Pathogenesis
- Mycobacterium research and diagnosis
- NF-κB Signaling Pathways
- Stoma care and complications
- Empathy and Medical Education
- Cutaneous lymphoproliferative disorders research
- Acne and Rosacea Treatments and Effects
University of North Carolina at Chapel Hill
2016-2025
Hidradenitis Suppurativa Foundation
2021-2024
Mayo Clinic in Florida
2024
Wake Forest University
2024
University of North Carolina Health Care
2020-2023
Creative Commons
2021
University of California, Los Angeles
2021
Atkins (United States)
2021
Central University of the Caribbean
2020
University of Ottawa
2019
Hidradenitis suppurativa (HS) is a chronic inflammatory disease with high burden for patients and limited existing therapeutic options.To evaluate the efficacy safety of bimekizumab, monoclonal IgG1 antibody that selectively inhibits interleukin 17A 17F in individuals moderate to severe HS.This phase 2, double-blind, placebo-controlled randomized clinical trial an active reference arm was performed from September 22, 2017, February 21, 2019. The study included 2- 4-week screening period,...
Validated, inclusive and easy-to-use outcomes for hidradenitis suppurativa are essential both in the clinical trial setting practice. The continuous IHS4 is a validated tool that dynamically assesses nodules/abscesses/draining tunnels classifies disease severity as mild/moderate/severe. However, dichotomous often required trials reporting.To develop validate outcome based on can be used settings day-to-day practice.De-identified data from PIONEER-I -II studies were accessed through Vivli....
Hidradenitis suppurativa (HS) is a common and severely morbid chronic inflammatory skin disease that reported to be highly heritable. However, the genetic understanding of HS insufficient, limited genome-wide association studies (GWASs) have been performed for HS, which not identified significant risk loci.
Patients with Down syndrome (DS) have increased incidence of inflammatory conditions, including hidradenitis suppurativa (HS), which may require biologic medications for optimal disease management. This retrospective cohort study evaluated 27 patients DS and co-morbid HS demonstrated that biologics are well tolerated effective in this cohort.
<h3>Importance</h3> Surgical intervention is frequently needed to treat hidradenitis suppurativa (HS). Patient satisfaction high based on previous studies, but reports of patient impressions clinic-based operative experiences and postoperative recovery are limited. <h3>Objective</h3> To characterize impressions, outcomes, time after surgical treatment HS examine characteristics associated with outcomes. <h3>Design, Setting, Participants</h3> This retrospective cohort study included patients...
Importance Various surgical approaches for hidradenitis suppurativa (HS) have been described in the literature, but nomenclature is inconsistent. Excisions as wide, local, radical, and regional with variable descriptions of margins. Deroofing procedures various though approach are generally more uniform. No international consensus has formed to globally standardize terminology HS procedures. Lack such agreement may contribute misunderstanding or misclassification procedural research studies...
Hidradenitis suppurativa (HS) is a chronic, inflammatory condition characterized by recurrent nodules, sinus tracts, comedones, and scarring. often associated with pain decreased quality of life. Limited clinical trial data exist regarding the management acute HS lesions, but experience prospective case series suggest that intralesional triamcinolone may be useful.To compare efficacy to placebo for treatment lesions.This double-blind, randomized, placebo-controlled comparing 10 mg/mL, 40...
Hidradenitis suppurativa (HS) is an inflammatory skin disease with a profound effect on patients' quality of life. The patient's journey to manage HS often complex and unsuccessful, which motivates the aim this research gain insight into unmet needs relevant treatment considerations from perspective patients healthcare professionals (HCPs).Individual semi-structured interviews were conducted HCPs experienced in treating understand perceived care identify important attributes. Prioritization...
Summary Background and aims Extra‐intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, treatment targets is limited. Methods As starting point for national EIM study network, an interdisciplinary expert panel 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, patient representatives was...
Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction their treatment. However, factors related to treatment satisfaction have not been explored.To measure associations between and clinical treatment-related characteristics among HS.Treatment was evaluated utilizing data from a cross-sectional global survey HS recruited 27 institutions, mainly referral centres, in 14 different countries October 2017 July 2018. The primary outcome patients' self-reported overall...
Hidradenitis suppurativa is a chronic immune-mediated inflammatory skin disease with prevalence of 0.1–1%, characterized by nodules and abscesses in the axillae, groin, inframammary areas, sometimes developing into tunnels (or fistulas) scars. Because hidradenitis more common women those aged 18–40 years, obstetrician–gynecologists (ob-gyns) have opportunity to diagnose, educate, initiate treatment, coordinate care ancillary health professionals. The recently published North American...
Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It validated datasets of adalimumab and placebo-treated HS patients. External validation is an important aspect clinical outcomes. Objectives: We aimed to externally validate novel IHS4-55 non-biologic treated dataset Methods: Data from previously published European-wide prospective study antibiotic treatment patients were used assess...